What is William Blair’s Estimate for Incyte Q1 Earnings?

Incyte Co. (NASDAQ:INCY) – Equities research analysts at William Blair issued their Q1 2025 earnings per share estimates for shares of Incyte in a research note issued on Monday, February 10th. William Blair analyst M. Phipps anticipates that the biopharmaceutical company will earn $0.66 per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Incyte’s current full-year earnings is $0.35 per share. William Blair also issued estimates for Incyte’s Q2 2025 earnings at $1.06 EPS, Q3 2025 earnings at $1.22 EPS and Q4 2025 earnings at $1.24 EPS.

Incyte (NASDAQ:INCY) last issued its quarterly earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.48). Incyte had a net margin of 0.80% and a negative return on equity of 0.63%.

Several other analysts also recently commented on the company. Wells Fargo & Company increased their target price on Incyte from $68.00 to $70.00 and gave the company an “equal weight” rating in a research note on Thursday, December 19th. StockNews.com cut Incyte from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Citigroup decreased their target price on Incyte from $97.00 to $88.00 and set a “buy” rating for the company in a research report on Tuesday. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Incyte in a report on Friday, January 10th. Finally, Royal Bank of Canada reduced their price target on shares of Incyte from $70.00 to $68.00 and set a “sector perform” rating for the company in a research note on Tuesday. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Incyte presently has a consensus rating of “Hold” and a consensus target price of $75.59.

Incyte Trading Up 4.1 %

NASDAQ:INCY opened at $69.05 on Thursday. Incyte has a 52 week low of $50.35 and a 52 week high of $83.95. The stock has a market cap of $13.30 billion, a price-to-earnings ratio of 493.25, a PEG ratio of 0.53 and a beta of 0.70. The company’s 50 day moving average price is $71.47 and its 200-day moving average price is $69.16. The company has a quick ratio of 1.82, a current ratio of 1.87 and a debt-to-equity ratio of 0.01.

Institutional Investors Weigh In On Incyte

Hedge funds have recently bought and sold shares of the business. Quintet Private Bank Europe S.A. purchased a new position in shares of Incyte in the 4th quarter worth $26,000. Global X Japan Co. Ltd. grew its position in Incyte by 144.7% in the fourth quarter. Global X Japan Co. Ltd. now owns 389 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 230 shares in the last quarter. R Squared Ltd purchased a new stake in Incyte during the fourth quarter valued at approximately $30,000. Brooklyn Investment Group purchased a new stake in Incyte during the third quarter valued at approximately $30,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Incyte in the 3rd quarter valued at approximately $33,000. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Insider Buying and Selling

In other news, EVP Steven H. Stein sold 12,352 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $72.69, for a total transaction of $897,866.88. Following the sale, the executive vice president now directly owns 66,967 shares of the company’s stock, valued at $4,867,831.23. This represents a 15.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Thomas Tray sold 650 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $69.31, for a total transaction of $45,051.50. Following the completion of the transaction, the insider now directly owns 23,312 shares of the company’s stock, valued at approximately $1,615,754.72. This trade represents a 2.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 19,695 shares of company stock worth $1,444,356. 17.60% of the stock is owned by insiders.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.